Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05411796 · ClinicalTrials.gov registry record · NA
In-use Cross-over Study of Two Different Menstrual Cups
A NA study, sponsored by Procter and Gamble.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
NCT05411796: Completed NA study, sponsored by Procter and Gamble.
NCT05411796 is a NA study that has completed, run by Procter and Gamble. The registered enrollment target is 65 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05411796, a NA study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study evaluated the safety and tolerability of two different menstrual cups on vaginal health
Primary Outcome
visually graded on a scale of 0 (no apparent erythema) to 4 (severe erythema)
Interventions
- DEVICE Tampax menstrual cup
- DEVICE Other menstrual cup
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2018-11-14 |
| Phase | NA |
What the finished NCT05411796 record still lists
NCT05411796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Tampax menstrual cup is the first listed.
NCT05411796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05411796 about?
NCT05411796 is a clinical study titled "In-use Cross-over Study of Two Different Menstrual Cups". This study evaluated the safety and tolerability of two different menstrual cups on vaginal health
What is the current status of trial NCT05411796?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2018-08-07. Estimated completion is 2018-11-14.
What interventions are being tested in trial NCT05411796?
The interventions under investigation include: Tampax menstrual cup (DEVICE), Other menstrual cup (DEVICE).
Who is sponsoring clinical trial NCT05411796?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05411796's enrollment target sits among peer trials
65 1144th of 2000 higher than 854 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI